Advances in melanoma immunotherapy: harnessing vaccination as a potential novel immunotherapeutic strategy
Melanoma, an aggressive form of skin cancer, demands innovative immunotherapeutic strategies to improve patient outcomes. This review explores recent advances in melanoma immunotherapy, with a particular focus on vaccination as a promising approach. It examines diverse vaccine platforms aimed at eliciting robust immune responses against melanoma-specific antigens, emphasizing the role of adjuvants in enhancing efficacy and overcoming resistance. The use of model organisms-especially murine models-is highlighted for their critical role in elucidating vaccine mechanisms, identifying novel antigens, and optimizing delivery systems. The review also discusses ongoing clinical trials targeting improved response rates and overall survival. Looking ahead, the integration of artificial intelligence and personalized medicine is proposed as a transformative direction, leveraging individual genetic, immunologic, and environmental factors to address current challenges. By summarizing key progress and outlining future research avenues, this review aims to inspire continued innovation in the development of safe, effective, and durable immunotherapeutic strategies for melanoma patients.
Authors
- Amal Kamal Abdel-Aziz
- Dima Abuelainain
- Mona Kamal Saadeldin
Institutions
- University of Notre Dame (US)
- Ain Shams University (EG)
- The Graduate Center, CUNY (US)
- Sam Houston State University (US)
Publication Details
- Journal
- Biochemical Pharmacology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1016/j.bcp.2026.117687
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00